Waters NYSE: WAT reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business revenue and adjusted earnings per share after results exceeded its prior guidance.
WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.
Waters Corporation (WAT) Q2 2026 Earnings Call Transcript
| Professional Services Industry | Industrials Sector | Udit Batra CEO | XETRA Exchange | US9418481035 ISIN |
| US Country | 7,900 Employees | - Last Dividend | 28 Aug 2000 Last Split | 16 Nov 1995 IPO Date |
Waters Corporation, established in 1958 and based in Milford, Massachusetts, operates globally, providing advanced analytical workflow solutions across Asia, the Americas, and Europe. The company is structured into two main segments: Waters and TA, through which it offers a broad spectrum of technology systems and support products tailored for scientific research and industrial applications. Waters Corporation's innovation in high and ultra-performance liquid chromatography, mass spectrometry (MS) technology, and assorted support products, including chromatography columns and consumables, is complemented by its service offerings, spanning post-warranty service plans to instrument maintenance. Moreover, the firm's commitment to advancing research and ensuring quality assurance across various sectors is epitomized by its range of thermal analysis, rheometry, and calorimetry instruments, alongside a suite of specialized software products. Serving a diverse clientele, from clinical and pharmaceutical researchers to environmental analysts, Waters Corporation plays a pivotal role in facilitating drug development, environmental testing, and quality assessment of consumer goods, promoting safety and innovation across industries.
These instruments form the backbone of analytical chemistry, particularly in the separation, identification, and quantification of compounds in samples. Waters Corporation designs, manufactures, and services such systems that are critical for drug discovery and development, clinical trials, protein analysis in disease processes, environmental testing, and nutritional safety analysis.
Essential for the effective operation of chromatography systems, these products include a variety of columns and other consumables that ensure precision and reliability in sample analysis across various laboratory applications.
Waters Corporation offers comprehensive service plans that extend beyond the warranty, providing maintenance and support for instruments to ensure their optimal performance and longevity.
The company also specializes in the design and production of instruments used for analyzing the physical properties of materials, such as their response to heat (thermal analysis), flow behavior (rheometry), and energy changes in chemical reactions (calorimetry). These instruments are invaluable in assessing the stability and suitability of materials for industrial, healthcare, and consumer goods applications, as well as for life science research.
Developing and supplying advanced software-based products that complement its range of instruments, Waters Corporation ensures seamless integration and enhanced functionality. This software facilitates data analysis and interpretation, contributing to the efficiency and effectiveness of laboratory workflows.